Susan Altschuller - 20 May 2022 Form 4 Insider Report for ImmunoGen, Inc.

Reporting relationship: SVP AND CFO
Issuer ticker: N/A
Reported as of: 20 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Dec 2022, 16:14:38 UTC
Prior SEC filing: 08 Feb 2022
Next SEC filing: 19 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Renee Lentini, Attorney-in-Fact

Filing notes and source

Key filing fact

Susan Altschuller filed Form 4 for ImmunoGen, Inc. on 27 Dec 2022.

Key facts

This page summarizes Susan Altschuller's Form 4 filing for ImmunoGen, Inc..
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 27 Dec 2022, 16:14.

Change

Previous filing in this sequence was filed on 08 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +41,250
Change %
Price: $0.000000
Shares after: 41,250
Date: 20 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,250
Exercise price: $4.74
Footnotes: F1

IMGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +82,500
Change %: +200%
Price: $0.000000
Shares after: 123,750
Date: 14 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 82,500
Exercise price: $4.74
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.

Footnote F2

On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.